Penicillin-Binding Protein Gene Alterations in Streptococcus uberis Isolates Presenting Decreased Susceptibility to Penicillin

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

Streptococcus uberis is an environmental pathogen commonly causing bovine mastitis, an infection that is generally treated with penicillin G. No field case of true penicillin-resistant S. uberis (MIC > 16 mg/liter) has been described yet, but isolates presenting decreased susceptibility (MIC of 0.25 to 0.5 mg/liter) to this drug are regularly reported to our laboratory. In this study, we demonstrated that S. uberis can readily develop penicillin resistance in laboratory-evolved mutants. The molecular mechanism of resistance (acquisition of mutations in penicillin-binding protein 1A [PBP1A], PBP2B, and PBP2X) was generally similar to that of all other penicillin-resistant streptococci described so far. In addition, it was also specific to S. uberis in that independent resistant mutants carried a unique set of seven consensus mutations, of which only one (Q(554)E in PBP2X) was commonly found in other streptococci. In parallel, independent isolates from bovine mastitis with different geographical origins (France, Holland, and Switzerland) and presenting a decreased susceptibility to penicillin were characterized. No mosaic PBPs were detected, but they all presented mutations identical to the one found in the laboratory-evolved mutants. This indicates that penicillin resistance development in S. uberis might follow a stringent pathway that would explain, in addition to the ecological niche of this pathogen, why naturally occurring resistances are still rare. In addition, this study shows that there is a reservoir of mutated PBPs in animals, which might be exchanged with other streptococci, such as Streptococcus agalactiae, that could potentially be transmitted to humans.

Knowledge Graph

Similar Paper

Penicillin-Binding Protein Gene Alterations in Streptococcus uberis Isolates Presenting Decreased Susceptibility to Penicillin
Antimicrobial Agents and Chemotherapy 2010.0
Genetic Heterogeneity in pbp Genes among Clinically Isolated Group B Streptococci with Reduced Penicillin Susceptibility
Antimicrobial Agents and Chemotherapy 2008.0
Diversity of Penicillin Binding Proteins among Clinical Streptococcus pneumoniae Strains from Portugal
Antimicrobial Agents and Chemotherapy 2008.0
First Molecular Characterization of Group B Streptococci with Reduced Penicillin Susceptibility
Antimicrobial Agents and Chemotherapy 2008.0
An Important Site in PBP2x of Penicillin-Resistant Clinical Isolates of Streptococcus pneumoniae : Mutational Analysis of Thr338
Antimicrobial Agents and Chemotherapy 2009.0
Promoter and Transcription Analysis of Penicillin-Binding Protein Genes in Streptococcus gordonii
Antimicrobial Agents and Chemotherapy 2007.0
Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam Antibiotics
Antimicrobial Agents and Chemotherapy 2008.0
Highly Variable Penicillin Resistance Determinants PBP 2x, PBP 2b, and PBP 1a in Isolates of Two Streptococcus pneumoniae Clonal Groups, Poland <sup>23F</sup> -16 and Poland <sup>6B</sup> -20
Antimicrobial Agents and Chemotherapy 2008.0
Staphylococcus aureus PBP4 Is Essential for β-Lactam Resistance in Community-Acquired Methicillin-Resistant Strains
Antimicrobial Agents and Chemotherapy 2008.0
Target Gene Sequencing To Characterize the Penicillin G Susceptibility of Neisseria meningitidis
Antimicrobial Agents and Chemotherapy 2007.0